Figure 6 . Anti-CXCL16 antibody ameliorated cecal ligation and
puncture (CLP)-induced severe sepsis. C57BL/6 mice were subjected to
severe CLP; and then 10 μg of anti-mouse CXCL16 monoclonal antibody was
injected intraperitoneally at 2 hour after severe CLP. IgG2A control
antibody was delivered in a similar way. (A) Survival of septic mice (n
= 12 per group) following administration with anti–CXCL16 antibody or
control antibody after severe CLP. Comparison between groups was
performed by Kaplan-Meier analysis followed by log-rank tests. Results
are representative of three independent experiments.p <0.05 when compared with septic mice treated with IgG
control. (B) Representative examples of hematoxylin and eosin–stained
lung, liver, and kidney tissues from septic mice (n = 6) treated with or
without anti-CXCL16 neutralizing antibodies after severe CLP. (C)
Histological scores for lung, liver, and kidney in septic mice (n = 6)
treated with or without anti-CXCL16 neutralizing antibodies after severe
CLP. p <0.05, p <0.01 when compared with
septic mice treated with isotypical IgG control (Mann-Whitney U test).
(D) ALT, AST, LDH, and creatinine levels in septic mice (n = 6) treated
with or without anti- CXCL16 neutralizing antibodies after severe CLP.p <0.05, p <0.01 when compared with
septic mice treated with isotypical IgG control (Mann-Whitney Utest).